| OPCML at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer. | ovarian, |
| OPCML gene promoter methylation may play an important role in the carcinogenesis of cervical carcinoma. OPCML may be a cervical carcinoma-associated candidate tumor suppressor gene. | cervical, |
| The OPCML tumor suppressor negatively regulates a specific spectrum of receptor tyrosine kinases in ovarian cancer cells by binding to their extracellular domain. | ovarian, |
| The Tumor-Suppressor Protein OPCML Potentiates Anti-EGFR- and Anti-HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer | breast,ovarian, |
| OPCML is a broad tumor suppressor, which is frequently inactivated by methylation in multiple malignancies. | None |
| Inactivating mutations and X-ray crystal structure of the tumor suppressor OPCML reveal cancer-associated functions | None |
| Human opioid-binding protein/cell adhesion molecule (OPCML) is expressed in many tissues and localizes to the plasma membrane. It is a putative tumor suppressor that acts on receptor tyrosine kinases, influencing cell cycle arrest, apoptosis, and migration. Its expression is silenced epigenetically in cancer, inferring potential diagnostic, prognostic, and therapeutic roles. [Review] | None |
| Emerging roles for the GPI-anchored tumor suppressor OPCML in cancers | None |